Humanized antibodies to treat diabetes, range of tissue injuries
SerpinB13 is a protease inhibitor linked to autoimmune inflammation and Type 1 diabetes (T1D).
Studies in mice treated with anti-serpinB13 antibody revealed increase in the number of pancreatic progenitor cells, expansion of islet mass and improved resistance to severe diabetes.
In humans, native anti-serpinB13 activity is associated with a slower progression to onset of T1D and a slower decline in the residual beta cell function in the first year after diabetes onset. Additionally, the serpinB13 antibody has regenerative properties.
The regenerative potential of serpinB13 antibody was underscored in studies on bone fracture and skin ulcers. In both instances, antibody treatment markedly accelerated bone and skin healing. Taken together, the serpinB13 antibody has potential therapeutic applications ranging from diabetes to acute forms of tissue injury.
- Treats Type 1 Diabetes:> Administration of antibodies results in reduced inflammation and increased beta-cell proliferation.
- Based on identified human biomarkers: Therapy complements natural autoantibodies associated with positive disease outcomes.
- Reduced host immune reactivity: The humanized serpinB13 antibody mitigates immunogenic effects in humans.
- Inflammatory bowel disease
- Skin burn injury
- Bone fractures
- Hereditary hair loss